Proteus Digital Health™, NHS England and UK Trade & Investment to Bring Transformative Digital Health Technology to the UK

  Proteus Digital Health™, NHS England and UK Trade & Investment to Bring
  Transformative Digital Health Technology to the UK

Business Wire

LONDON -- March 10, 2014

Leading digital medicines company Proteus Digital Health™ is partnering with
Eastern Academic Health Science Network (EAHSN), The Northern Health Science
Alliance (NHSA) and Oxford University, Oxford University Hospitals NHS Trust
and Oxford Academic Health Science Network (OAHSN) to bring digital health
technology and global operations and manufacturing to the UK.

Each of the organisations will team up with Proteus Digital Health™ to assess
the value of digital medicines in supporting patients’ medication taking
behaviours and daily activity while realising significant cost savings.

Proteus Digital Health™ intends to employ 200 highly skilled individuals at
its first international manufacturing site in the UK. The international
manufacturing facility will serve as a new hub for the global
digitalmedicines industry,transferring significant investment and know-how
to the UK.

“I’m delighted that Proteus Digital Health is establishing their first
international manufacturing site here in Britain, creating 200 highly skilled
jobs,” said Prime Minister David Cameron. “It’s proof that our work to attract
high-tech business to the UK is providing real benefits for people at home –
all part of our long term economic plan.”

The partnership was facilitated by NHS England and the Life Science Investment
Organisation (LSIO) of UK Trade & Investment (UKTI). “This partnership will
clearly benefit patients, the NHS and the economy,” said Miles Ayling,
Director of Innovation at NHS England.

"Our lives are becoming increasingly digital, a variety of sectors have
already undergone fundamental changes through the introduction of innovative
digital approaches,” said Dr. Hakim Yadi, Chief Executive Officer of the
Northern Health Science Alliance. “Healthcare is clearly the next sector to
benefit from such changes and we are delighted to be working with Proteus to
pioneer the use of this technology at scale in the North of England to the
benefit of patients and the NHS."

Proteus Digital Health™ is working to create a new category of products,
services and data systems that have the potential to significantly improve the
effectiveness of existing pharmaceutical treatments. Called digital medicines,
these new pharmaceuticals will contain a tiny sensor that communicates with a
patch to deliver vital information about an individual’s medication-taking
behaviour and how their body is responding to therapy.

“The technology platform Proteus offers will allow digital health to become a
reality, giving patients a role in managing their disease and allowing the
managementof chronic disease and drug compliance to be delivered in a much
more cost effective way,” said Sir John Bell, Regius Professor of Medicine,
Oxford University. “Oxford University and the Oxford Academic Health Science
Network look forward to collaborating with Proteus to bring these exciting
technologies to patients and improve their health.”

“Some patients have trouble taking their medicines for a host of different
reasons, which may result in decreased effect of the therapy and unnecessary
costs,” said Dr. Robert Winter, Managing Director, EAHSN. “Through this
partnership, we will explore both the clinical and economic value of digital
health technology in the treatment of hypertension.”

Andrew Thompson, President and Chief Executive Officer of Proteus Digital
Health™, said: “This marks an important milestone in the emergence of the
global digital medicines industry. We are honoured to be working with leaders
who are positioning the UK and NHS at the forefront of digital innovation in
healthcare by delivering tools that empower patients and their families.”

“This is fantastic news for Proteus Digital Health™ and for the UK,” said Dr.
Mark Treherne, Chief Executive Officer of UKTI’s LSIO. “This move signifies a
new economic opportunity and the growing momentum of transformational
healthcare technology in the UK. Having a company of Proteus Digital Health™
calibre operating in the UK is a huge testament to the life science ecosystem
and the global lead that the UK takes in supporting the adoption of new
innovative products.”

About the Northern Health ScienceAlliance

The Northern Health Science Alliance Ltd (NHSA) is a new
partnershipestablished by the leading Universities and NHS Hospital Trusts in
the North ofEngland to improve the health and wealth ofthe region by
creating aninternationally recognized life science and healthcare system. The
company actsas focal point for NHSA members, including the four Academic
Health Science Networks in the North of England and partner organisations to
work collaborativelyonprojects that leverage the combined potential of the
North. The NHSA supports its partners inworking together to harness the
resources, infrastructure, intellectualcapital and experience of the whole
Northern healthcare ecosystem.

Furtherinformation is available at:

Oxford University Hospitals NHS Trust (OUH)

Oxford University Hospitals NHS Trust (OUH) is one of the largest acute
teaching trusts in the UK, with a national and international reputation for
the excellence of its services and its role in patient care, teaching and
research. The Trust supports world-leading research programmes. It works in
close partnership with the University of Oxford and is a leading centre for
cancer, neurosciences, diabetes, genetics and many other fields. Research
themes of particular strength are: cancer, cardiovascular science, diabetes,
endocrinology & metabolism, infection and immunology, musculoskeletal science,
neuroscience and reproduction and development. The Trust has been designated
as a major trauma centre and is one of four UK centres for craniofacial
surgery. The Trust employs 11,000 staff and consists of four hospitals: the
Churchill Hospital, John Radcliffe Hospital and Nuffield Orthopaedic Centre in
Oxford and the Horton General Hospital in Banbury.

Further information is available at:

About Proteus Digital Health™

Proteus Digital Health™ is pioneering a new category of products, services and
data systems based on ingestible computing. Its core technology – the digital
health feedback system – provides an unprecedented view into an individual’s
personal health choices and physiologic response, allowing patients to better
manage their health and more effectively collaborate with caregivers and
clinicians, while enabling new information-based business models. Proteus has
received a CE mark in Europe and FDA market clearance in the U.S. for its
wearable and Ingestible Sensor™ devices.Headquartered in Redwood City,
Calif., Proteus is privately held and funded by Carlyle, Essex Woodlands,
Kaiser Permanente®, Medtronic®, Novartis®, Otsuka®, Oracle®, ON Semiconductor®
and other investors.

Further information is available at:

Eastern Academic Health Science Network

The EAHSN has been set up to promote the adoption, diffusion and spread of
innovation into and throughout the NHS. Our aim is to use innovation to reduce
unwarranted variation in service provision and to help build the new paradigms
for an improved health service for the next generation. Drawing on this, and
our successful innovation hub and Small Business Research Initiative (SBRI)
programmes, we will grow wealth and economic value, leveraging sustainable
improvements in healthcare. The EAHSN will improve health outcomes, bridging
the vital gap between world-class research and top-quality clinical care.
Delivery is dependent on a transformational model based on four established
biomedical and clinical communities, with a track record of excellence in
research, education, health services and industry.


UK Trade & Investment (UKTI) is the government department that helps UK-based
companies trade in the global economy and assists overseas companies bring
their high-quality investment to the UK. UKTI has established a dedicated unit
focused on UK life science - the UKTI Life Science Investment Organisation
(LSIO). The LSIO works with overseas companies to identify research,
development and delivery partners and provides support in every element of
investing and working in the UK.

Further information is available at:


Proteus Digital Health, Inc.
Robin Suchan,+1 650-637-6221
Manager, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.